BIOPHYTIS.jpg
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study
June 30, 2021 17:00 ET | BIOPHYTIS SA
The Company signed contracts for the manufacturing of registration batches in view of the potential application for Emergency Use Authorization to FDA and/or Conditional Marketing Authorization to...
BIOPHYTIS.jpg
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021
June 30, 2021 17:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”),a clinical-stage biotechnology company...
BIOPHYTIS.jpg
Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
June 18, 2021 20:00 ET | BIOPHYTIS SA
PARIS and Cambridge, Mass., June 19, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company...
BIOPHYTIS.jpg
BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis
May 12, 2021 02:00 ET | BIOPHYTIS SA
This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy dataThe Company is to report the recommendation from the DMC based on its...
BIOPHYTIS.jpg
BIOPHYTIS - Results of the Combined General Meeting on May 10, 2021
May 11, 2021 02:00 ET | BIOPHYTIS SA
PARIS, France and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “company”), a clinical-stage biotechnology...
BIOPHYTIS.jpg
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
April 30, 2021 02:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., April 30, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at...
BIOPHYTIS.jpg
Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in Dry AMD
April 29, 2021 02:00 ET | BIOPHYTIS SA
DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potentialBiophytis plans to initiate Phase 1 clinical trial in the second half of 2021 PARIS...
BIOPHYTIS.jpg
Biophytis - Convening of Another Combined General Meeting at a Later Date
April 27, 2021 02:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at...
BIOPHYTIS.jpg
Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021
April 26, 2021 02:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that are...
BIOPHYTIS.jpg
BIOPHYTIS Identifies False Report Regarding COVA study
April 13, 2021 17:00 ET | BIOPHYTIS SA
PARIS and CAMBRIDGE, Mass., April 13, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of...